MX2022004971A - Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular. - Google Patents

Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular.

Info

Publication number
MX2022004971A
MX2022004971A MX2022004971A MX2022004971A MX2022004971A MX 2022004971 A MX2022004971 A MX 2022004971A MX 2022004971 A MX2022004971 A MX 2022004971A MX 2022004971 A MX2022004971 A MX 2022004971A MX 2022004971 A MX2022004971 A MX 2022004971A
Authority
MX
Mexico
Prior art keywords
calcification
evolution
inhibition
prevention
treatment
Prior art date
Application number
MX2022004971A
Other languages
English (en)
Spanish (es)
Inventor
Bestard Joan Perelló
Roca Carolina Salcedo
Reynés Miquel David Ferrer
Original Assignee
Sanifit Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics S A filed Critical Sanifit Therapeutics S A
Publication of MX2022004971A publication Critical patent/MX2022004971A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022004971A 2019-11-11 2020-11-10 Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular. MX2022004971A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382990.0A EP3818983A1 (en) 2019-11-11 2019-11-11 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
PCT/EP2020/081674 WO2021094331A1 (en) 2019-11-11 2020-11-10 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification

Publications (1)

Publication Number Publication Date
MX2022004971A true MX2022004971A (es) 2022-06-08

Family

ID=68610132

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004971A MX2022004971A (es) 2019-11-11 2020-11-10 Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular.

Country Status (10)

Country Link
US (2) US20220339171A1 (https=)
EP (2) EP3818983A1 (https=)
JP (1) JP7808029B2 (https=)
KR (1) KR20220099957A (https=)
CN (1) CN114585367A (https=)
AU (1) AU2020381775B2 (https=)
CA (1) CA3156023A1 (https=)
IL (1) IL292118B1 (https=)
MX (1) MX2022004971A (https=)
WO (1) WO2021094331A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113377A1 (en) * 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
CN113712976B (zh) * 2021-10-21 2023-02-24 中国人民解放军海军军医大学 小分子化合物肌醇六磷酸酯钠水合物在制备抗SARS-CoV-2药物中的应用
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs
US20250217970A1 (en) * 2023-12-28 2025-07-03 Case Western Reserve University Risk prediction of heart failure

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ES2124303T3 (es) 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
BR112014007405B1 (pt) 2011-09-29 2021-07-13 Eth Zurich Composto, mio-inositol-pentaquisfosfato-2-peg(400) e forma farmacêutica
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
US9364490B2 (en) * 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
JP6893037B2 (ja) 2015-12-11 2021-06-23 エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ Ｃ．ｄｉｆｆｉｃｉｌｅ感染のための４，６−ジ−（Ｏ−チオホスフェート）−イノシトール−１，２，３，５−テトラ−Ｏ−スルフェート
DK3386548T3 (da) 2015-12-11 2021-05-25 Eth Zuerich Inositol-derivater til anvendelse i patologisk krystallisering

Also Published As

Publication number Publication date
IL292118B1 (en) 2026-04-01
CN114585367A (zh) 2022-06-03
AU2020381775B2 (en) 2026-03-26
JP7808029B2 (ja) 2026-01-28
EP3818983A1 (en) 2021-05-12
JP2023500020A (ja) 2023-01-04
WO2021094331A1 (en) 2021-05-20
IL292118A (en) 2022-06-01
KR20220099957A (ko) 2022-07-14
EP4058030A1 (en) 2022-09-21
CA3156023A1 (en) 2021-05-20
US20220339171A1 (en) 2022-10-27
AU2020381775A1 (en) 2022-04-14
US20250295676A1 (en) 2025-09-25

Similar Documents

Publication Publication Date Title
MX2022004971A (es) Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular.
Zekri et al. The anti-tumour effects of zoledronic acid
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
AR110419A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
BRPI0518315B8 (pt) compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica
MX2021014175A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
BR112017019343A2 (pt) uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
MX390145B (es) Formulaciones para la administracion de eflornitina
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
AR110800A1 (es) MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2’-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
MX2025001181A (es) Regimenes de dosificacion que comprenden un inhibidor kat6 para el tratamiento de cancer
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
NZ755637A (en) Compounds and their use in the treatment of schistosomiasis
BR112022008095A2 (pt) Métodos e composições para o tratamento da síndrome de rett
MX2020002336A (es) Composicion lipolitica que contiene derivados de fosfocolina.
MX2024005721A (es) Inositol fosfatos para el tratamiento de calcificacion ectopica.
BR112022006458A2 (pt) Compostos de inositol fosfato para uso no tratamento, inibição da progressão ou prevenção da calcificação cardiovascular
MX2022015275A (es) Compuestos de 1,2,4-trioxano y composiciones que comprenden los mismos para uso en la prevencion y el tratamiento del cancer.
MX2025004758A (es) Compuestos y su uso para el tratamiento de hemoglobinopatias